SciSparc (SPRC) Retained Earnings (2016 - 2025)
SciSparc (SPRC) posted Retained Earnings of -$87.2 million for Q4 2025, down 3.38% sequentially from -$84.3 million in Q2 2025, and down 16.24% YoY from -$104.1 million in Q4 2024.
SciSparc (SPRC) Retained Earnings (2016 - 2025) Analysis & Trends
SciSparc has reported Retained Earnings for 10 years, with the latest figure at -$87.2 million in Q4 2025.
- Quarterly Retained Earnings fell 16.24% year-over-year to -$87.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$87.2 million (down 16.24% YoY) and the FY2025 annual result came in at -$87.2 million, down 16.24% from the prior year.
- Retained Earnings slipped to -$87.2 million in Q4 2025 per SPRC's latest filing, from -$84.3 million in the prior quarter.
- Over five years, Retained Earnings peaked at -$57.8 million in Q2 2021 and troughed at -$87.2 million in Q4 2025.
- A 5-year average of -$69.5 million and a median of -$66.7 million in 2022 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2023 and 2025: Retained Earnings increased 0.43% in 2023, then slipped 16.87% in 2025.
- Over 5 years, Retained Earnings stood at -$61.0 million in 2021, then retreated by 4.25% to -$63.6 million in 2022, then decreased by 8.06% to -$68.7 million in 2023, then declined by 9.15% to -$75.0 million in 2024, then dropped by 16.24% to -$87.2 million in 2025.
- According to Business Quant data, Retained Earnings over the past three periods registered -$87.2 million, -$84.3 million, and -$75.0 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.81 Bn | 131.96 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 86.56 Bn | 78.56 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 65.72 Bn | 60.53 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.75 Bn | 53.61 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.76 Bn | 28.45 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.59 Bn | 10.19 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.63 Bn | 26.47 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.24 Bn | 26.40 Bn | - | 4.38 Bn |
| 10 | SciSparc | 807,202.50 | 807,202.50 | - | -87.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -87.15 Mn |
| Jun 30, 2025 | -84.30 Mn |
| Dec 31, 2024 | -74.98 Mn |
| Jun 30, 2024 | -72.13 Mn |
| Dec 31, 2023 | -68.69 Mn |
| Jun 30, 2023 | -66.45 Mn |
| Dec 31, 2022 | -63.57 Mn |
| Sep 30, 2022 | -61.49 Mn |
| Jun 30, 2022 | -66.74 Mn |
| Dec 31, 2021 | -60.98 Mn |
| Jun 30, 2021 | -57.84 Mn |
| Dec 31, 2020 | -55.19 Mn |
| Jun 30, 2020 | -54.34 Mn |
| Dec 31, 2019 | -51.71 Mn |
| Jun 30, 2019 | -49.54 Mn |
| Mar 31, 2019 | -49.05 Mn |
| Dec 31, 2018 | -46.91 Mn |
| Sep 30, 2018 | -43.39 Mn |
| Jun 30, 2018 | -41.65 Mn |
| Mar 31, 2018 | -40.44 Mn |